Litcius/Paper detail

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Qing-Yun Chong, Ze-Hui Kok, Ngoc-Linh-Chi Bui, Xiaoqiang Xiang, Andrea Li‐Ann Wong, Wei Peng Yong, Gautam Sethi, Peter E. Lobie, Lingzhi Wang, Boon-Cher Goh

2020Pharmacological Research108 citationsDOI

Topics & Concepts

PalbociclibCyclin-dependent kinaseCDK inhibitorCyclin-dependent kinase 4KinaseBreast cancerMedicineCancerPharmacologyCyclin-dependent kinase 6Cancer researchFulvestrantCell cycleEstrogen receptorMetastatic breast cancerInternal medicineOncologyBiologyCyclin-dependent kinase 2BiochemistryAdvanced Breast Cancer TherapiesCancer-related Molecular PathwaysHER2/EGFR in Cancer Research
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib | Litcius